
SFNM NE Series: Therapies for neonatal encephalopathy: Targeting the latent, secondary and tertiary phases of evolving brain injury
Practice Points: Assessment of therapies across a range of animal models, with careful safety and pharmacokinetic studies, is vital before clinical translation. Clinical neuroprotection trials